{"id":30548,"date":"2017-03-30T11:02:39","date_gmt":"2017-03-30T09:02:39","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=30548"},"modified":"2017-04-11T18:17:34","modified_gmt":"2017-04-11T16:17:34","slug":"sanofi-vuole-vendere-la-bu-generici-europa-la-merck-kgaa-la-bu-biosimilari","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/sanofi-vuole-vendere-la-bu-generici-europa-la-merck-kgaa-la-bu-biosimilari\/","title":{"rendered":"Sanofi wants to sell the generics BU in Europe and Merck KGaA the biosimilars BU"},"content":{"rendered":"<h1>Sanofi accelerates the sale of 2 billion European generics<\/h1>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright\" src=\"http:\/\/s3.reutersmedia.net\/resources\/r\/?m=02&amp;d=20170329&amp;t=2&amp;i=1178491154&amp;w=780&amp;fh=&amp;fw=&amp;ll=&amp;pl=&amp;sq=&amp;r=LYNXMPED2S0SJ\" alt=\"A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014. REUTERS\/Christian Hartmann\/File Photo\" width=\"303\" height=\"191\" \/>According to sources cited by Reuters, Sanofi is seeking advisors for the sale of its European generics business which could be worth more than \u20ac2 billion. The French pharmaceutical giant had anticipated its intention to sell the business as early as last October and the choice of banks is expected by the end of the month. Sanofi closed Wednesday&#039;s session in Paris by 0.43%<\/p>\n<p>Related news:\u00a0<a href=\"http:\/\/uk.reuters.com\/article\/uk-sanofi-m-a-generics-idUKKBN16F1P3?il=0\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Sanofi gears up for European generic drugs unit sale \u2013 sources<\/span><\/a><\/p>\n<p class=\"article-headline\"><a href=\"http:\/\/www.reuters.com\/article\/us-sanofi-m-a-generics-idUSKBN1701A4\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Sanofi hires advisors for European generic drugs unit sale: sources<\/span><\/a><\/p>\n<h1>Merck KGaA towards the sale of the biosimilars BU<\/h1>\n<p>L<img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"http:\/\/qtxasset.com\/2017-01\/11132HIGH_MERCKINNOVATIONCE.JPG\" alt=\"Merck kgaa\" width=\"374\" height=\"249\" \/>And the rumors are true: Merck KGaA wants to sell the biosimilars business unit. The German pharmaceutical company announced in its 2016 annual report that it is at an advanced stage of the negotiations. In October, the pharmaceutical company reportedly requested the help of JPMorgan Chase &amp; Co. to search for potential buyers. According to some sources, Merck could obtain a figure of around one billion dollars. Merck KGaA has been working with Indian generics company Dr. Reddy&#039;s to develop biosimilars since 2012, but the partnership has not brought any products to market so far. The pipeline includes a copy of Abbvie&#039;s Humira currently in phase 3.<\/p>\n<p><strong>The market<\/strong><br \/>\nIn this sector Merck KGaA is <em>followers <\/em>in the US market: Novartis, Sandoz and Pfizer already have biosimilars on the market and Amgen&#039;s copy of Humira is awaiting launch after the FDA approval obtained in September. As the market begins to fill up, companies still catching up may need to cut prices in order to get a piece of the pie. Merck KGaA is not the only pharmaceutical company to try to hedge against biosimilars. Late last month Brent Saunders, chief executive officer of Allergan, said his company will likely do the same thing after it finishes developing the four oncology drug copies in partnership with Amgen. The biosimilars BU may not be the only one Merck will say goodbye to in the near future. \u201cEvery division of the company is under continuous review,\u201d said CEO Stefan Oschmann.<\/p>\n<p>Related news:\u00a0<a href=\"http:\/\/www.fiercepharma.com\/pharma\/merck-kgaa-advanced-talks-to-sell-off-biosims-unit-and-others-could-follow\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Merck KGaA in advanced talks to sell off biosims unit\u2014and others could follow<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2017-02-23\/bristol-myers-looms-as-pharma-s-next-megadeal-as-activists-join\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Bristol-Myers Looms as Pharma&#039;s Next Megadeal as Activists Join<\/span><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Sanofi accelera sulla vendita dei generici europei da 2 mld Secondo fonti citate da Reuters, Sanofi sarebbe alla ricerca di advisor per la vendita delle attivit\u00e0 europee nei farmaci generici che potrebbero valere oltre 2 miliardi di euro. Il colosso farmaceutico francese aveva anticipato l&#8217;intenzione di cedere il business gi\u00e0 lo scorso ottobre e la &hellip;<\/p>","protected":false},"author":4,"featured_media":27666,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[53],"class_list":["post-30548","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-fusioniacquisizioni"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/30548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=30548"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/30548\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/27666"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=30548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=30548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=30548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}